JP2020505342A - 腫瘍微小環境内の機能不全抗原特異的ｃｄ８＋ｔ細胞 - Google Patents

腫瘍微小環境内の機能不全抗原特異的ｃｄ８＋ｔ細胞 Download PDF

Info

Publication number
JP2020505342A
JP2020505342A JP2019537357A JP2019537357A JP2020505342A JP 2020505342 A JP2020505342 A JP 2020505342A JP 2019537357 A JP2019537357 A JP 2019537357A JP 2019537357 A JP2019537357 A JP 2019537357A JP 2020505342 A JP2020505342 A JP 2020505342A
Authority
JP
Japan
Prior art keywords
cells
antibody
lag
tumor
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019537357A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020505342A5 (enExample
Inventor
ガジェウスキー，トーマス
ウィリアムス，ジェイソン
ホートン，ブレンダン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Original Assignee
University of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Chicago filed Critical University of Chicago
Publication of JP2020505342A publication Critical patent/JP2020505342A/ja
Publication of JP2020505342A5 publication Critical patent/JP2020505342A5/ja
Priority to JP2022139514A priority Critical patent/JP2022184862A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019537357A 2017-01-17 2018-01-17 腫瘍微小環境内の機能不全抗原特異的ｃｄ８＋ｔ細胞 Pending JP2020505342A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022139514A JP2022184862A (ja) 2017-01-17 2022-09-01 腫瘍微小環境内の機能不全抗原特異的ｃｄ８＋ｔ細胞

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762447199P 2017-01-17 2017-01-17
US62/447,199 2017-01-17
PCT/US2018/014008 WO2018186924A1 (en) 2017-01-17 2018-01-17 Dysfunctional antigen-specific cd8+ t cells in the tumor microenvironment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022139514A Division JP2022184862A (ja) 2017-01-17 2022-09-01 腫瘍微小環境内の機能不全抗原特異的ｃｄ８＋ｔ細胞

Publications (2)

Publication Number Publication Date
JP2020505342A true JP2020505342A (ja) 2020-02-20
JP2020505342A5 JP2020505342A5 (enExample) 2021-03-04

Family

ID=63712313

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019537357A Pending JP2020505342A (ja) 2017-01-17 2018-01-17 腫瘍微小環境内の機能不全抗原特異的ｃｄ８＋ｔ細胞
JP2022139514A Pending JP2022184862A (ja) 2017-01-17 2022-09-01 腫瘍微小環境内の機能不全抗原特異的ｃｄ８＋ｔ細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022139514A Pending JP2022184862A (ja) 2017-01-17 2022-09-01 腫瘍微小環境内の機能不全抗原特異的ｃｄ８＋ｔ細胞

Country Status (6)

Country Link
US (3) US11566077B2 (enExample)
EP (1) EP3570887A4 (enExample)
JP (2) JP2020505342A (enExample)
CN (1) CN110740748A (enExample)
CA (1) CA3049445A1 (enExample)
WO (1) WO2018186924A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL265800B2 (en) 2016-10-11 2023-10-01 Agenus Inc Anti-LAG-3 antibodies and methods of using them
JP7297672B2 (ja) 2017-04-13 2023-06-26 アジェナス インコーポレイテッド 抗ｃｄ１３７抗体およびその使用方法
US20220023342A1 (en) * 2018-11-30 2022-01-27 Institut Gustave Roussy Anti-neuropilin-1 and anti-programmed cell death-1 combination therapy for treating cancer
WO2020146772A1 (en) * 2019-01-11 2020-07-16 The Johns Hopkins University Neuritin regulation of t cell anergy and t regulatory cell function
CN109913414A (zh) * 2019-03-21 2019-06-21 吉林省银丰生物工程技术有限公司 肝癌afp特异性人工抗原递呈细胞诱导试剂盒
US20210130438A1 (en) * 2019-10-28 2021-05-06 The Broad Institute, Inc. Pan-cancer t cell exhaustion genes
WO2021146386A1 (en) * 2020-01-14 2021-07-22 The Trustees Of Columbia University In The City Of New York Compositions and methods for targeted protein stabilization by redirecting endogenous deubiquitinases
CN115666655A (zh) * 2020-03-17 2023-01-31 俄亥俄州立创新基金会 用于治疗兴奋性毒性的设计者胞外囊泡
CN111781358A (zh) * 2020-07-13 2020-10-16 张瑜 Xab2蛋白作为卵巢癌预后和/或预测铂类耐药标志物
CN112481375B (zh) * 2020-08-27 2024-02-20 江苏大学 一种胃癌标志物及其应用
CN114350616A (zh) * 2022-01-24 2022-04-15 深圳市先康达生命科学有限公司 一种免疫细胞及其制备方法和应用
CN114814231B (zh) * 2022-03-08 2024-08-27 上海交通大学医学院附属瑞金医院 维甲酸诱导基因i在癌症治疗中的应用
CN114561389A (zh) * 2022-03-15 2022-05-31 南通市肿瘤医院 Vrk1表达抑制剂及其应用
CN115631857B (zh) * 2022-04-01 2023-06-23 洛兮医疗科技(杭州)有限公司 甲状腺癌cd8+t细胞免疫相关基因预后预测模型
CN114720691B (zh) * 2022-05-10 2022-12-09 深圳粒影生物科技有限公司 一种检测生物标志物的试剂盒及其制备方法和应用
CN115449548A (zh) * 2022-09-20 2022-12-09 南京鼓楼医院 Stac2卵丘细胞在评估卵母细胞受精能力中的应用
CN117192127B (zh) * 2023-08-18 2024-06-14 肇庆医学高等专科学校 一种hcc治疗靶点的发现方法
CN119120385B (zh) * 2024-11-14 2025-03-14 四川大学华西医院 一种具有长效抑瘤效果的嵌合抗原受体t细胞及其制备方法和用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA877772B (en) 1986-10-23 1988-04-20 Amoco Corporation Target and background capture methods and apparatus for affinity assays
US20070072209A1 (en) 2005-07-07 2007-03-29 Ashlee Moses Methods of treatment and diagnosis of Kaposi's sarcoma (KS) and KS related diseases
WO2008133641A2 (en) * 2006-10-11 2008-11-06 Curagen Corporation Antibodies directed to gpnmb and uses thereof
US8637084B2 (en) * 2009-07-14 2014-01-28 Asahi Kasei Medical Co., Ltd. Treatment method for epithelial cancerous organism
WO2011159877A2 (en) * 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
JP2012025694A (ja) * 2010-07-23 2012-02-09 Asahi Kasei Kuraray Medical Co Ltd 癌治療剤
NZ714128A (en) * 2010-09-09 2017-10-27 Pfizer 4-1bb binding molecules
SG190793A1 (en) 2010-11-11 2013-07-31 Agency Science Tech & Res Targeting metabolic enzymes in human cancer
EP2911669B1 (en) * 2012-10-26 2024-04-10 The University of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
EP2970909A4 (en) * 2013-03-15 2017-02-15 The University of Chicago Methods and compositions related to t-cell activity
EP3686219A1 (en) 2014-02-04 2020-07-29 Pfizer Inc Combination of a pd-1 antagonist and a 4-1bb agonist for treating cancer
CN114107424A (zh) * 2014-10-08 2022-03-01 诺华股份有限公司 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途
JP6647315B2 (ja) * 2015-01-09 2020-02-14 イーチュービクス コーポレイション 組み合わせ免疫療法のための方法および組成物
US20180371093A1 (en) * 2015-12-17 2018-12-27 Novartis Ag Antibody molecules to pd-1 and uses thereof
JP2019518791A (ja) 2016-06-03 2019-07-04 ザ・ブリガム・アンド・ウィメンズ・ホスピタルＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ Ｋｌｒｇ１シグナリングセラピー

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. Vol. 3, Suppl 2, JPN6022007785, 2015, pages 328, ISSN: 0004904097 *
JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. Vol. 3, Suppl 2, JPN6022007786, 2015, pages 10, ISSN: 0004904096 *
岡山医学会雑誌, vol. 125, JPN6022007784, 2013, pages 13 - 18, ISSN: 0004904098 *

Also Published As

Publication number Publication date
EP3570887A1 (en) 2019-11-27
CN110740748A (zh) 2020-01-31
JP2022184862A (ja) 2022-12-13
US20230416389A1 (en) 2023-12-28
US20250011452A1 (en) 2025-01-09
CA3049445A1 (en) 2018-10-11
US11566077B2 (en) 2023-01-31
EP3570887A4 (en) 2020-11-25
US20200010557A1 (en) 2020-01-09
WO2018186924A1 (en) 2018-10-11

Similar Documents

Publication Publication Date Title
JP2022184862A (ja) 腫瘍微小環境内の機能不全抗原特異的ｃｄ８＋ｔ細胞
ES2967467T3 (es) Combinación de una terapia celular y un compuesto inmunomodulador
ES2961666T3 (es) Métodos para determinar la dosificación de células CAR-T
JP2023078394A (ja) Ｃａｒ－ｔ細胞の調節方法
US11946936B2 (en) Beta-catenin inhibitors in cancer immunotherapy
BR112020008638A2 (pt) receptores de antígenos quiméricos específicos para antígenos de maturação de células b (bcma)
KR20220032642A (ko) 종양 특이적 세포 고갈을 위한 항 cd25 fc 감마 수용체 이중특이적 항체
CN112203680A (zh) 用于细胞疗法的表型标记和相关方法
CN111246862A (zh) 产生基因工程化细胞组合物的方法和相关组合物
US20240302349A1 (en) Methods of assessing or monitoring a response to a cell therapy
CN116162168A (zh) 分子开关调控型嵌合抗原受体细胞和抗体的组合及其应用
CN111201438A (zh) 与和细胞疗法相关的毒性有关的制品和方法
US10746726B2 (en) Method for assessing therapeutic effect of anti-cancer agent having anti-CD4 antibody as active ingredient
Williams et al. c12) United States Patent
RU2795984C2 (ru) Изделия и способы для лечения с использованием адоптивной клеточной терапии
RU2774232C2 (ru) Способы модулирования cart-клеток
Williams et al. c19) United States c12) Patent Application Publication

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220301

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220527

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221025